Skip to main content
Equibles

UPC · Universe Pharmaceuticals INC · Metrics

Track UPC — free

Use UPC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research UPC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.34 -0.16 (-3.56%)
Rebalance outlook locked
Market Cap
$23.87M
Shares
5.02M
Volume · Oct 5 7846 Avg daily vol (3M) 802.75K

UPC metrics

45 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.50
Market cap
$23.87M

Price action

20 metrics
Price change (1W)
-5.3%
Price change (30D)
+11.7%
Price change (3M)
-28.8%
Price change (6M)
+42.4%
Price change (YTD)
+18.1%
Price change (1Y)
+0.2%
Trailing year
Price change (5Y)
—
52-week high
$12.18
52-week low
$2.25
Change from 52-week high
-63.1%
Change from 52-week low
+100.3%
Annualized volatility
360.5%
Annualized volatility (3M)
240.6%
Beta
3.7
RSI (14D)
47.3
Price vs SMA 50
-7.3%
Price vs SMA 200
+16.4%
Avg volume (3M)
802,751
Relative volume
0.1
Average dollar volume
$4.33M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
5.02M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.0
reciprocal yield 235,187.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
35.3%
Operating margin
-16.3%
Trailing 12 months
Net margin
-20.6%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$99,637.36

Growth

11 metrics
Revenue growth YoY
-22.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3,174.9%
Year over year · more shares
Revenue CAGR (3Y)
+663.4%
Revenue CAGR (5Y)
+257.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-6.5%
Return on assets
-5.3%
Debt / equity
—
Current ratio
4.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
3.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$33.59B
Total assets
$69.30B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
4
13F filer change QoQ
+4
Institutional ownership
0.7%

Short interest

3 metrics
Short interest
1.5%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
52 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1809616 CUSIP G9442G138